{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-022118","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.077938+00:00","generated_at":"2026-05-16T20:43:34.878529+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Imunon posts Q3 net loss of $3.4M, cash $5.3M; Phase 3 ovarian cancer study enrollment ahead","bullets":["Net loss of $3.4M ($1.16/sh) in Q3 2025 vs $4.8M ($3.76/sh) in Q3 2024; operating expenses down 30% to $3.5M.","Cash and equivalents $5.3M as of Sept 30, 2025; $4.5M raised from warrant exercises and ATM; runway into Q1 2026.","Phase 3 OVATION 3 study for IMNN-001 in advanced ovarian cancer enrollment exceeding expectations; Phase 2 data showed 13-month OS benefit.","R&D Day on Nov 10 highlighted investigator optimism and translational data; new data presented at SITC and AACR.","PlaCCine DNA vaccine platform proof-of-concept data presented; actively seeking partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-022118","json":"https://secwatch.observer/filing/0001493152-25-022118.json","markdown":"https://secwatch.observer/filing/0001493152-25-022118.md","text":"https://secwatch.observer/filing/0001493152-25-022118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315225022118/0001493152-25-022118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315225022118/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:43:34.878529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}